文献速递银屑病与炎症性皮肤病

Anumigilimab治疗化脓性汗腺炎或掌跖脓疱病的1b期安全性及药代动力学研究

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-07-21

这项1b期开放标签重复给药研究纳入39例中性粒细胞驱动的皮肤病患者(HS 22例,PPP 17例),评估新型抗G-CSFR抗体anumigilimab的安全性、药代动力学和探索性临床反应。结果显示总体耐受良好,无严重治疗相关不良事件,药理学呈剂量依赖性,HS和PPP中观察到探索性临床应答信号,但研究无安慰剂对照且样本量小,不足以统计确证疗效。

要点

  • Anumigilimab在中性粒细胞驱动的HS和PPP患者中总体耐受良好,无严重治疗相关不良事件。
  • 最常见治疗相关不良事件为疲乏和中性粒细胞减少,均自行缓解,未观察到中性粒细胞减少与感染的关联。
  • 药代动力学和中性粒细胞绝对值下降呈剂量依赖性,抗药抗体检出可忽略。

核心结论

  • Anumigilimab在HS或PPP患者中总体耐受良好,无严重治疗相关安全性担忧,并显示剂量依赖性药理学。
  • HS和PPP中观察到临床应答,但属探索性信号发现,研究不足以统计确证疗效且缺乏安慰剂对照。

研究设计与样本

  • 1b期开放标签重复给药研究(NCT03972280),含15周治疗期和9周随访期。
  • 纳入39例患者(HS n=22;PPP n=17),入组标准为IHS4评分≥4或ppPASI评分≥12。
  • ≥10例患者完成anumigilimab 0.3 mg/kg IV每21天一次(队列1)后,经药代动力学/药效学建模确定队列2剂量为0.6 mg/kg。
  • 主要终点为治疗中出现的不良事件(TEAEs),次要终点为药代动力学和免疫原性,探索性终点为药效学和临床应答。

主要发现

  • 最常见相关TEAEs为疲乏和中性粒细胞减少(均n=7),均自行缓解,未观察到中性粒细胞减少与感染的关联。
  • 无死亡或严重治疗相关TEAEs发生,抗药抗体存在可忽略。
  • Anumigilimab暴露和中性粒细胞绝对值下降(药效学终点)呈剂量依赖性。
  • 探索性分析中,57.9%的HS患者(第15周有数据者n=11/19)达到≥50% HS临床应答,IHS4评分下降40.3%,PPP患者ppPASI评分下降40.4%;临床应答不呈剂量依赖。

临床怎么用

  • Anumigilimab在HS和PPP中显示可接受的安全性及剂量依赖性药理学,支持后续随机安慰剂对照试验验证疗效。
  • 治疗相关疲乏和中性粒细胞减少多可自行缓解,用药期间仍需关注中性粒细胞变化。

局限性

  • 研究未设安慰剂对照,且样本量小,不足以统计确证疗效。
  • 临床应答为探索性信号发现,应答不呈剂量依赖,可能受基线特征不平衡和小样本量影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report the first study of anumigilimab, a novel anti-G-CSFR antibody, in patients with neutrophil-driven skin diseases [hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP)]. METHODS: This phase 1b, open-label, repeat-dose study (NCT03972280) comprised 15-week treatment and 9-week follow-up periods. Enrolled patients had International HS Severity Score System (IHS4) score ≥4 or PPP Area and Severity Index (ppPASI) score ≥12. After ≥10 patients completed anumigilimab 0.3 mg/kg IV at 21-day intervals (Cohort 1), pharmacokinetic/pharmacodynamic modelling determined the Cohort 2 dose (0.6 mg/kg). Primary endpoints were treatment-emergent adverse events (TEAEs). Secondary endpoints were pharmacokinetics and immunogenicity. Exploratory endpoints were pharmacodynamics and clinical response. RESULTS: Of 39 patients (HS, n = 22; PPP, n = 17), 33 patients (84.6%) experienced 198 TEAEs. Sixteen patients (41.0%) experienced 70 anumigilimab-related TEAEs; the most common were fatigue and neutropenia (both n = 7), which resolved spontaneously, and no association between neutropenia and infections was observed. No deaths or serious treatment-related TEAEs occurred. Presence of antidrug antibodies was negligible. Anumigilimab exposure and absolute neutrophil count reduction (pharmacodynamic endpoint) were dose dependent. In signal-finding exploratory analyses, 57.9% of patients with HS (n = 11/19 with data at Week 15) achieved ≥50% HS Clinical Response, IHS4 score decreased by 40.3%, and patients with PPP experienced a 40.4% reduction in ppPASI score. These clinical responses were not dose dependent, possibly due to imbalanced baseline characteristics and small sample size. CONCLUSIONS: Anumigilimab was generally well tolerated in patients with HS or PPP, with no serious treatment-related safety concerns, and demonstrated dose-dependent pharmacology. While clinical responses in HS and PPP were observed, it should be noted that these observations were exploratory and signal-finding in nature. Importantly, the study was not powered to statistically confirm efficacy and lacked a placebo control, underscoring the need for future randomized, placebo-controlled trials to validate these preliminary signal-finding observations. Hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP) are skin diseases that substantially affect patients' lives. Inflammation is a normal response to injury or infection. But inflammation can sometimes occur without injury or infection, resulting in long‐term diseases such as HS and PPP. A molecule called granulocyte colony‐stimulating factor (G‐CSF) drives inflammation in HS and possibly PPP. Blocking G‐CSF therefore may have the potential to improve symptoms. A novel drug called anumigilimab blocks the activity of G‐CSF. We used anumigilimab to treat 39 participants with HS or PPP in Australia and Europe. Our main goal was to see whether anumigilimab has any unwanted effects. Participants received 5five injections of anumigilimab, which were given every 3 weeks. Anumigilimab was not associated with any serious safety concerns. Sixteen patients had unwanted effects related to anumigilimab, which cleared up by themselves. The most common of these were tiredness and low levels of neutrophils (a type of white blood cell). Anumigilimab levels in blood, and its effects on neutrophil levels, were proportional to the amount of drug given. Several participants with HS or PPP appeared to benefit from receiving the drug. In conclusion, our results suggest that anumigilimab may be able to benefit people with HS or PPP. However, a placebo was not used in this small study. Anumigilimab requires investigation in larger studies with a placebo in order to further determine its safety and effectiveness.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kern JS, Thomsen SF, Kokolakis G, et al. Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study. J Eur Acad Dermatol Venereol. 2026. PMID: 42478283. doi:10.1111/jdv.70594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。